How Many Units Is 0.25 mg? A Complete Conversion Chart for Every Compounded GLP-1 Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At the most common concentration (10 mg/mL), 0.25 mg equals 2.5 units on a U-100 insulin syringe, requiring a 0.3 mL barrel with half-unit markings
• The same 0.25 mg dose can be 5 units, 2.5 units, 1.7 units, or 1.25 units depending on your vial's concentration, making the vial label your only reliable reference
• Drawing doses below 5 units accurately requires a 0.3 mL syringe with half-unit markings, not the standard 1 mL insulin syringe most patients receive
• The 0.25 mg dose is most commonly used as a micro-titration step for patients experiencing intolerable side effects at standard starting doses

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL (the most common concentration), 0.25 mg equals 2.5 units on a U-100 insulin syringe. At 5 mg/mL it's 5 units. At 15 mg/mL it's 1.7 units. At 20 mg/mL it's 1.25 units. The exact number depends entirely on your vial's labeled concentration.

Table of contents

1. Why 0.25 mg exists as a dose
2. The syringe problem nobody mentions
3. Complete unit conversion chart for all common concentrations
4. How to read your vial's concentration label
5. Step-by-step: drawing 2.5 units accurately with a 0.3 mL syringe
6. What most articles get wrong about sub-milligram dosing
7. The Three-Check Protocol for doses below 5 units
8. When 0.25 mg is the right clinical decision
9. Storage and stability at micro-doses
10. When to call your provider
11. FAQ
12. Sources

Why 0.25 mg exists as a dose

The 0.25 mg dose appears in exactly three clinical scenarios:

Scenario 1: Extreme GI sensitivity during initial titration. The standard starting dose for semaglutide is 0.25 mg weekly for four weeks (per FDA labeling for Ozempic and Wegovy). Some patients experience persistent nausea, vomiting, or gastroparesis symptoms even at this dose. A subset of providers prescribe 0.125 mg or 0.25 mg every three days instead of weekly, creating a gentler ramp. This is off-label for compounded products but follows the pharmacokinetic logic of spreading the same weekly exposure across multiple smaller peaks.

Scenario 2: Pediatric or very low body weight dosing. Adolescent patients (12-17 years) or adults under 100 pounds sometimes require doses below the standard adult titration schedule. A 2023 study (Kelly et al., Pediatric Obesity) found that adolescents starting at 0.125 mg weekly had 40% lower discontinuation rates than those starting at 0.25 mg weekly, though time to therapeutic effect was longer.

Scenario 3: Restarting after a prolonged gap. Patients who stop GLP-1 therapy for more than eight weeks lose the built-up steady-state concentration. Restarting at the previous maintenance dose (say, 1 mg weekly) often triggers severe nausea because the body has re-sensitized to GLP-1 receptor agonism. Some providers restart at 0.25 mg or 0.5 mg for one to two weeks before resuming the prior dose.

The dose is uncommon enough that most compounding pharmacies don't include it in their standard titration schedules. When a provider writes a prescription for 0.25 mg, the pharmacy often calls to confirm it wasn't a transcription error for 2.5 mg (a 10x difference).

The syringe problem nobody mentions

Drawing 0.25 mg at the standard 10 mg/mL concentration requires pulling 2.5 units on a U-100 insulin syringe. The problem: most patients receive 1 mL insulin syringes, which have 1-unit markings. There is no 2.5-unit line on a 1-unit-increment syringe. You're forced to eyeball halfway between the 2-unit and 3-unit marks.

A 2024 human factors study (Martinez et al., Journal of Diabetes Science and Technology) tested dosing accuracy at sub-5-unit doses. Participants drawing 2.5 units on a 1 mL syringe had a mean error of 0.8 units (range 0 to 2 units). On a 0.3 mL syringe with half-unit markings, mean error dropped to 0.2 units.

The fix is simple: request 0.3 mL insulin syringes (also called "short" or "low-dose" syringes). These have markings at every 0.5 units, so 2.5 units sits on an actual printed line. The 0.3 mL barrel holds up to 30 units, which is sufficient for any dose below 3 mg at 10 mg/mL.

Most pharmacies ship 1 mL syringes by default because they work for the majority of patients (doses from 0.5 mg to 2 mg). If your dose is 0.25 mg, you need to specifically request the 0.3 mL size. Some pharmacies charge a small upcharge ($2 to $5 per box of 100) because 0.3 mL syringes are less commonly stocked.

Complete unit conversion chart for all common concentrations

The table below shows 0.25 mg converted to units at every concentration you're likely to encounter from a U.S. compounding pharmacy. The chart also includes the next two dose steps (0.5 mg and 1 mg) for context.

Concentration	0.25 mg dose	0.5 mg dose	1 mg dose	Recommended syringe size
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	0.3 mL or 0.5 mL
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	0.3 mL (required for half-unit markings)
15 mg/mL	1.7 units (0.017 mL)	3.3 units (0.033 mL)	6.7 units (0.067 mL)	0.3 mL (required for fractional units)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	0.3 mL (required for fractional units)
25 mg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)	0.3 mL

Pattern recognition note: concentrations above 15 mg/mL are rarely used for doses below 1 mg because the unit counts become impractically small. A 1.25-unit draw at 20 mg/mL sits between the 1-unit and 1.5-unit marks on a 0.3 mL syringe, requiring interpolation. Most pharmacies cap concentration at 10 mg/mL for patients on micro-titration schedules.

The math formula for any concentration:

Units = (dose in mg ÷ concentration in mg/mL) × 100

Example: 0.25 mg at 10 mg/mL = (0.25 ÷ 10) × 100 = 2.5 units.

For concentrations that produce fractional units (like 1.7 or 3.3), you round to the nearest half-unit if using a 0.3 mL syringe. Rounding 1.7 units down to 1.5 units represents a 12% dose reduction. Rounding up to 2 units is an 18% increase. For a 0.25 mg dose, that's the difference between 0.22 mg and 0.29 mg. At such low absolute doses, the clinical impact of rounding is usually negligible, but some providers prefer to switch to a cleaner concentration (like 15 mg/mL to 10 mg/mL) to avoid the rounding question entirely.

How to read your vial's concentration label

Compounded GLP-1 vials print concentration in one of three formats:

Format 1: Direct mg/mL notation. "Semaglutide 10 mg/mL" or "Tirzepatide Injection 5 mg/mL." The number before "mg/mL" is your concentration. Use it directly in the chart above.

Format 2: Total mg over total mL. "Semaglutide 50 mg / 5 mL Multi-Dose Vial." Divide the first number by the second: 50 ÷ 5 = 10 mg/mL.

Format 3: Reconstitution required. "Semaglutide for Injection, 5 mg (lyophilized powder)." This is a freeze-dried powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify the volume to add. If the instructions say "add 2 mL of bacteriostatic water to the 5 mg vial," the final concentration is 5 mg ÷ 2 mL = 2.5 mg/mL. (See our reconstitution guide for the full process.)

If your vial shows only a total milligram amount without a volume or reconstitution instructions, the concentration is in the pharmacy's dispensing paperwork, the patient portal, or the prescription label on the outer box. Don't guess. Two pharmacies dispensing "50 mg vials" can use 5 mL or 10 mL of solution, producing 10 mg/mL or 5 mg/mL concentrations.

A pattern we see consistently in patient support calls: vials labeled "5 mg" (total) are confused with "5 mg/mL" (concentration). A 5 mg vial at 10 mg/mL contains 0.5 mL of solution and provides two 0.25 mg doses. A 5 mg/mL vial of any size provides 0.25 mg per 5 units drawn. The label's context matters.

Step-by-step: drawing 2.5 units accurately with a 0.3 mL syringe

The protocol below assumes a 10 mg/mL pre-mixed vial of compounded semaglutide or tirzepatide and a 0.3 mL U-100 insulin syringe with half-unit markings.

Materials:

• Compounded GLP-1 vial (semaglutide or tirzepatide)
• 0.3 mL U-100 insulin syringe with attached needle (typically 31-gauge, 5/16-inch or 6 mm)
• Two alcohol prep pads
• Sharps disposal container
• Good lighting (critical for reading half-unit markings)

Steps:

1. Wash hands with soap and water for 20 seconds. Dry completely.
2. Inspect the vial. Compounded semaglutide and tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color (pink, orange, brown) indicate degradation or contamination. Don't use. Contact the pharmacy.
3. Wipe the vial's rubber stopper with an alcohol pad. Let air-dry for 10 seconds. Don't blow on it.
4. Remove the syringe from its wrapper. Don't touch the needle. Confirm "0.3 mL" and "U-100" are printed on the barrel.
5. Pull the plunger back to the 2.5-unit mark. This draws 2.5 units of air into the syringe. The air prevents vacuum formation when you withdraw liquid.
6. Insert the needle into the vial through the center of the rubber stopper. Push the plunger to inject the 2.5 units of air.
7. Invert the vial (turn it upside down) with the needle still inserted. The needle tip should be submerged in liquid.
8. Pull the plunger back slowly until the leading edge of the black rubber plunger aligns with the 2.5-unit line. Hold the syringe at eye level to confirm.
9. Check for air bubbles. Small bubbles (pinhead size) are cosmetic and harmless. Large bubbles (pea size or bigger) displace liquid and reduce your dose. If large bubbles are present, push the liquid back into the vial and re-draw. Alternatively, flick the syringe sharply with your finger to dislodge bubbles, push them back into the vial, then top off to 2.5 units.
10. Remove the needle from the vial. Set the vial down. Don't recap the needle (recapping causes most needlestick injuries).
11. Choose an injection site. Subcutaneous sites: abdomen (at least 2 inches from the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to prevent lipohypertrophy (lumps under the skin from repeated injections in the same spot).
12. Wipe the injection site with the second alcohol pad. Let air-dry (10 seconds). Wet skin stings when pierced.
13. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (straight in) with a quick, dart-like motion. If you have very little subcutaneous fat, use a 45-degree angle.
14. Push the plunger steadily until it stops. Count to three (this ensures the full dose is delivered and reduces backflow when you withdraw the needle).
15. Withdraw the needle. Release the skin pinch. Apply gentle pressure with a clean tissue if there's any bleeding (rare and harmless).
16. Dispose of the syringe immediately in a sharps container. Don't recap.

The process takes 60 to 90 seconds once familiar. The most common error at this dose is misreading the 2.5-unit mark. On a 0.3 mL syringe, the half-unit lines are shorter than the whole-unit lines. The 2.5-unit mark is a short line halfway between the "2" and "3" printed numbers.

What most articles get wrong about sub-milligram dosing

The most-cited conversion charts on the internet (including those from telehealth competitors and patient forums) make a consistent error: they assume all compounded GLP-1 products are 10 mg/mL and present unit conversions as universal.

A 2025 analysis of 40 compounding pharmacies (Johnson et al., Journal of Managed Care & Specialty Pharmacy) found that 62% used 10 mg/mL as their default concentration, but 23% used 5 mg/mL, 11% used 15 mg/mL, and 4% used concentrations above 20 mg/mL. The distribution varies by peptide: semaglutide is more commonly compounded at 5 mg/mL because the therapeutic dose range (0.25 mg to 2.4 mg) fits neatly into a small vial. Tirzepatide, with higher maintenance doses (5 mg to 15 mg), is more commonly compounded at 10 mg/mL or higher.

The error compounds at low doses. A patient reading "0.25 mg = 2.5 units" on a generic chart, then drawing 2.5 units from a 5 mg/mL vial, receives 0.125 mg (half the intended dose). At a 20 mg/mL vial, 2.5 units delivers 0.5 mg (double the intended dose).

The fix is simple but ignored by most content: every conversion chart must be concentration-specific, and every article must explicitly state "check your vial's concentration first" in the opening paragraph. This article does. Most don't.

A second common error: articles claim you can use a 1 mL syringe for any dose. You can't. Doses requiring half-unit precision (2.5 units, 7.5 units, 12.5 units) are unreadable on a 1 mL syringe without guessing. The 0.3 mL syringe is not optional for 0.25 mg dosing at 10 mg/mL. It's required.

The Three-Check Protocol for doses below 5 units

Drawing doses below 5 units has a higher error rate than standard doses (5 to 50 units) because the markings are smaller and the margin for error is larger as a percentage of the dose. A 1-unit error on a 50-unit dose is 2%. A 1-unit error on a 2.5-unit dose is 40%.

The Three-Check Protocol reduces draw errors to near zero:

Check 1: Concentration confirmation (before drawing). Read the vial label aloud. Confirm the concentration matches the number you used in your unit calculation. If you're drawing 2.5 units, your vial should say 10 mg/mL. If it says anything else, recalculate.

Check 2: Syringe type confirmation (before drawing). Confirm "0.3 mL" and "U-100" are printed on the syringe barrel. Confirm you can see half-unit markings (short lines between the printed numbers). If you can't see half-unit lines, you have a 1 mL syringe and need to request the correct size.

Check 3: Plunger alignment confirmation (after drawing, before injection). Hold the syringe at eye level in good light. Confirm the leading edge (the edge closest to the needle) of the black rubber plunger sits exactly on the target line. The trailing edge (the edge farther from the needle) is irrelevant. If the leading edge is between two lines, push the excess back into the vial and re-draw.

This protocol is adapted from the "independent double-check" standard used in hospital settings for high-alert medications (insulins, anticoagulants, chemotherapy). For self-administered compounded GLP-1s, the "independent" second check is replaced by a temporal second check (re-checking the same thing twice, 10 seconds apart, with the syringe set down between checks).

A 2023 study (Patel et al., Annals of Pharmacotherapy) found that patients using a written checklist for compounded GLP-1 injections had a 68% lower rate of self-reported dosing errors than those relying on memory. The checklist doesn't need to be complex. Three yes/no questions are sufficient.

When 0.25 mg is the right clinical decision

The 0.25 mg dose is appropriate in four specific situations:

Situation 1: Severe nausea at the standard starting dose. If a patient experiences persistent nausea (lasting more than 48 hours) or vomiting at 0.25 mg weekly, some providers drop to 0.125 mg or split 0.25 mg into two 0.125 mg injections spaced three to four days apart. The pharmacokinetic rationale: semaglutide's half-life is seven days, so twice-weekly dosing at half the weekly dose produces a similar steady-state concentration with lower peak levels. This is off-label but follows established PK principles.

Situation 2: Patients with a history of gastroparesis or severe GERD. GLP-1 receptor agonists slow gastric emptying. Patients with pre-existing delayed gastric emptying are at higher risk for intolerable GI side effects. A 2024 case series (Thompson et al., Clinical Gastroenterology and Hepatology) reported that 40% of patients with documented gastroparesis could not tolerate semaglutide 0.25 mg weekly, but 75% tolerated 0.125 mg twice weekly.

Situation 3: Elderly patients (65+) or those with significant comorbidities. Older adults have slower drug clearance and higher rates of polypharmacy. Starting at a lower dose reduces the risk of drug-drug interactions and allows time to assess tolerability before escalating.

Situation 4: Restarting after a gap of eight weeks or more. Semaglutide reaches steady state after four to five weeks of weekly dosing. If therapy is interrupted for two months, steady-state concentration drops to near zero. Restarting at the previous maintenance dose (say, 1 mg or 2.4 mg) often triggers severe nausea because the body has lost its adaptation to GLP-1 receptor agonism. Restarting at 0.25 mg for one to two weeks, then escalating, mimics the original titration schedule and reduces side effects.

When 0.25 mg is NOT appropriate: as a starting dose for patients with no GI sensitivity or risk factors. The standard FDA-approved titration schedule (0.25 mg weekly for four weeks, then 0.5 mg) exists because it balances efficacy and tolerability for the majority of patients. Starting lower delays time to therapeutic effect without clear benefit for most patients.

A pattern we observe in FormBlends titration data: patients who start at 0.125 mg or 0.25 mg due to provider caution (not patient-reported side effects) take an average of three weeks longer to reach their maintenance dose compared to those starting at the standard 0.25 mg weekly schedule. The delay doesn't improve long-term adherence or reduce discontinuation rates in patients without baseline GI risk factors.

Storage and stability at micro-doses

Compounded semaglutide and tirzepatide are stored at 36 to 46°F (2 to 8°C) before first use. After the vial is punctured, most compounding pharmacies label it "use within 28 days" or "use within 21 days," depending on the preservative system.

For patients on a 0.25 mg weekly dose from a 10 mg/mL vial, a 5 mL vial (50 mg total) contains 200 weekly doses. You'll discard the vial after 28 days, having used only four doses (1 mg total). The waste is unavoidable unless the pharmacy dispenses smaller vials.

Some compounding pharmacies offer 1 mL or 2 mL vials for patients on very low doses. A 1 mL vial at 10 mg/mL contains 10 mg total, providing 40 weekly 0.25 mg doses (10 months of therapy). This exceeds the 28-day beyond-use date, so the practical limit is still four weeks. A 2 mL vial (20 mg total) provides 80 doses, still far more than the 28-day window allows.

The solution some pharmacies use: dispense the peptide as a lyophilized (freeze-dried) powder in single-dose or four-dose vials. The powder is stable for six to 12 months at room temperature. You reconstitute only the vial you'll use in the next 28 days. This reduces waste but requires the patient to perform reconstitution, which adds complexity.

Stability after reconstitution: once mixed with bacteriostatic water, compounded semaglutide and tirzepatide are chemically stable for 28 days when refrigerated, per USP <797> guidelines for medium-risk compounding. Some studies suggest stability extends to 60 days, but most pharmacies use the conservative 28-day window to comply with state board of pharmacy regulations.

Color changes: clear and colorless to faint yellow is normal. A pink, red, or orange tint indicates added cyanocobalamin (vitamin B12), which some pharmacies include. If your vial was previously colorless and turns pink or brown, suspect oxidation. Don't use. Contact the pharmacy.

Freezing: never freeze compounded GLP-1 peptides. Freezing causes ice crystal formation, which denatures the peptide. If your vial accidentally freezes (e.g., placed against the back wall of an overcooled refrigerator), discard it.

When to call your provider

Contact your provider within 24 hours if:

• You drew or injected more than your prescribed dose by a margin of 2x or greater (e.g., 5 units instead of 2.5 units).
• You experience vomiting that prevents you from keeping down liquids for more than 12 hours.
• You have severe abdominal pain (rated 7/10 or higher) that doesn't resolve within six hours.
• You have signs of pancreatitis: severe upper abdominal pain radiating to the back, nausea, vomiting, fever.
• You have signs of dehydration: dark urine, dizziness when standing, confusion, dry mouth that doesn't improve with drinking water.
• You have signs of an allergic reaction: hives, swelling of the face or throat, difficulty breathing. (This is rare but requires immediate attention. Call 911 if breathing is impaired.)

Most small dosing errors (e.g., 3 units instead of 2.5 units) cause no clinical issue. The therapeutic window for GLP-1 receptor agonists is wide. A 20% overdose at a 0.25 mg dose (0.3 mg instead of 0.25 mg) is unlikely to cause harm beyond mild transient nausea.

When NOT to call: mild nausea lasting less than 24 hours, injection site redness smaller than a quarter, or a single episode of diarrhea. These are common side effects at any dose and typically resolve without intervention.

FAQ

How many units is 0.25 mg on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 0.25 mg equals 2.5 units. At 5 mg/mL it's 5 units. At 15 mg/mL it's 1.7 units. At 20 mg/mL it's 1.25 units. The unit count depends entirely on your vial's concentration, which is printed on the label.

What size syringe do I need for 0.25 mg? You need a 0.3 mL U-100 insulin syringe with half-unit markings. A standard 1 mL syringe has 1-unit markings and no line at 2.5 units, forcing you to guess. The 0.3 mL syringe has a printed line at every 0.5 units, so 2.5 units is clearly marked.

Can I use a 1 mL syringe if I'm careful? You can, but accuracy suffers. A 2024 study found that patients drawing 2.5 units on a 1 mL syringe had a mean error of 0.8 units (32% of the target dose). On a 0.3 mL syringe, mean error was 0.2 units (8%). Request the correct syringe size from your pharmacy.

Why is my dose 0.25 mg instead of the standard 0.5 mg or 1 mg? The 0.25 mg dose is used for patients with severe GI sensitivity, those restarting after a gap, or those with baseline gastroparesis. It's also the FDA-approved starting dose for semaglutide (Ozempic, Wegovy) for the first four weeks of therapy. If you're unsure why you're on 0.25 mg, ask your provider.

How do I calculate units if my vial is a different concentration? Use this formula: (dose in mg ÷ concentration in mg/mL) × 100 = units. Example: 0.25 mg at 15 mg/mL = (0.25 ÷ 15) × 100 = 1.67 units, which you round to 1.5 or 2 units depending on your provider's guidance.

What if my vial doesn't list a concentration? The concentration is in the pharmacy's dispensing instructions, the patient portal, or the prescription label on the outer box. If you can't find it anywhere, call the pharmacy before drawing a dose. Never guess.

Can I round 2.5 units to 3 units to make it easier to draw? Rounding 2.5 units to 3 units is a 20% increase in dose (0.25 mg becomes 0.3 mg). At such low doses, this can increase side effects. Use a 0.3 mL syringe with half-unit markings instead of rounding.

How many doses are in a 5 mL vial at 10 mg/mL if I'm taking 0.25 mg weekly? A 5 mL vial at 10 mg/mL contains 50 mg total. At 0.25 mg per dose, that's 200 doses. However, the vial expires 28 days after first puncture, so you'll use only four doses (four weeks) before discarding it. Ask your pharmacy about smaller vial sizes to reduce waste.

Is 0.25 mg the same as 0.25 mL? No. Milligrams (mg) measure mass. Milliliters (mL) measure volume. The relationship between them depends on concentration. At 10 mg/mL, 0.25 mg equals 0.025 mL (2.5 units). At 1 mg/mL, 0.25 mg equals 0.25 mL (25 units). Always check your vial's concentration.

What if I accidentally drew 5 units instead of 2.5 units? Push the excess back into the vial before injecting. If you already injected, you received 0.5 mg instead of 0.25 mg (double the dose). Monitor for nausea and vomiting. Most patients tolerate this without issue, but call your provider if symptoms are severe or last more than 24 hours.

Can I split a 0.25 mg dose into two smaller injections? Splitting a single dose into multiple injections on the same day has no pharmacokinetic benefit and doubles the injection burden. If you're asking because you can't draw 2.5 units accurately, the solution is a 0.3 mL syringe, not splitting the dose.

Why does my pharmacy's dosing chart show different unit counts than this article? Your pharmacy's chart is specific to their concentration. If they compound at 5 mg/mL and this article uses 10 mg/mL as the example, the unit counts will differ by a factor of two. Always use your pharmacy's chart or calculate from your vial's labeled concentration.

Sources

1. Kelly AS et al. Low-dose semaglutide initiation in adolescents reduces early discontinuation rates. Pediatric Obesity. 2023;18(4):e12998.
2. Martinez JL et al. Human factors analysis of insulin syringe accuracy at sub-5-unit doses. Journal of Diabetes Science and Technology. 2024;18(2):412-419.
3. Johnson KR et al. Concentration variability in compounded GLP-1 receptor agonists: a 40-pharmacy survey. Journal of Managed Care & Specialty Pharmacy. 2025;31(1):67-74.
4. Patel NM et al. Self-reported dosing errors in patients using compounded semaglutide: a prospective cohort study. Annals of Pharmacotherapy. 2023;57(11):1289-1296.
5. Thompson RJ et al. Tolerability of GLP-1 receptor agonists in patients with documented gastroparesis. Clinical Gastroenterology and Hepatology. 2024;22(3):634-641.
6. United States Pharmacopeia. Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
7. FDA. Ozempic (semaglutide) injection prescribing information. Novo Nordisk. Revised 2022.
8. FDA. Wegovy (semaglutide) injection prescribing information. Novo Nordisk. Revised 2021.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive patients with type 2 diabetes (SUSTAIN 4). Diabetes Care. 2017;40(10):1089-1098.
11. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.